Find policies, billing codes, payers, states, and providers
CPT 64615: Bilateral Chemical Denervation of Facial/Cervical Muscles
CPT code 64615 denotes bilateral chemical denervation of muscles innervated by the trigeminal, facial, cervical spinal, and accessory nerves, a procedure that produces targeted muscle paralysis. This intervention is clinically significant as a therapeutic option for conditions such as chronic migraine and other focal muscle hyperactivity disorders. Nationally, the code matters for ambulatory procedural billing, utilization monitoring, and coverage determinations tied to neuromuscular injection therapies.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise breakdown of clinical context and typical sites of service, plus the billing and policy implications that commonly arise for this type of procedure. The publication outlines benchmarks and reimbursement considerations, common payer coverage patterns, and practical coding elements associated with delivering bilateral chemical denervation under this CPT code.
The report provides guidance on where to find policy updates, common documentation and medical necessity themes that payers often require, and the clinical scenarios in which CPT code 64615 is applied. Data not available in the input will be clearly noted where applicable.
Customize your policy alerts
Sign up for cpt 64615 policy alerts
Get alerted when payer policies referencing 64615 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 64615 describes bilateral chemical denervation of muscles innervated by the trigeminal, facial, cervical spinal, and accessory nerves with the intent to produce muscle paralysis. The procedure typically involves targeted injections of a neuromuscular blocking agent to reduce muscle activity in facial and head/neck muscle groups.
-
Service type: Therapeutic chemical denervation / neuromuscular injection for muscle paralysis, often used for chronic migraine management and other medically indicated focal muscle hyperactivity.
-
Typical site of service: Outpatient clinic, physician office, or ambulatory surgery center where injectable procedures are performed under appropriate monitoring; may also be performed in hospital outpatient settings depending on clinical context.